Top in hem/onc: Convalescent plasma, early-onset colorectal cancer
A recent study showed no significant difference in COVID-19 disease severity, progression, mortality or hospitalization between high-risk patients who received convalescent plasma and those who received placebo.
A report on the data was the top story in hematology/oncology last week.
Another top story explored the biological differences between early-onset and average-onset colorectal cancer. Researchers reported that they were “genomically indistinguishable,” suggesting that more aggressive treatment for early-onset colorectal cancer is neither necessary nor effective.
Read these and more top stories in hematology/oncology below:
Early convalescent plasma fails to prevent COVID-19 progression in high-risk outpatients
COVID-19 convalescent plasma administered within 7 days of symptom onset did not appear to prevent disease progression among high-risk outpatients with COVID-19, according to study results published in The New England Journal of Medicine. Read more.
Early-onset colorectal cancer may not be biologically different from average-onset disease
Early-onset colorectal cancer did not appear genomically distinct from average-onset disease, according to results of a retrospective, single-institution analysis published in Journal of the National Cancer Institute. Read more.
Long-term effects of COVID-19 and cancer create population of ‘dual survivors’
The late effects of cancer and its treatment are well documented and may extend years beyond active treatment. Read more.
Commercial insurers pay more for cancer surgery at NCI centers vs. community hospitals
Insurers of patients with private insurance who underwent cancer surgery spent more per surgical episode at NCI centers than at community hospitals, according to study results published in JAMA Network Open. Read more.
Post-transplant cyclophosphamide increases risk for early cardiac events
Post-transplant cyclophosphamide reduced incidence of graft-versus-host disease but led to higher incidence of early cardiac events after allogeneic hematopoietic stem cell transplantation, according to study results. Read more.